TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.